Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 PEG Ratio is 2.33 as of Jul. 13, 2026, which is 16% below its 10-year median of 2.77. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $50.48 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 224 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks worse than 72.77% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for COSMOS Pharmaceutical's PEG Ratio or its related term are showing as below:
CSMYF'
s PEG Ratio Range Over the Past 10 Years
Min: 1.51 Med: 2.77 Max: 9.97
Current: 2.65
During the past 13 years, COSMOS Pharmaceutical's highest PEG Ratio was 9.97. The lowest was 1.51. And the median was 2.77.
CSMYF's PEG Ratio is ranked worse than 72.77% of 224
companies
in the Healthcare Providers & Services industry
Industry Median: 1.39
vs CSMYF: 2.65
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
COSMOS Pharmaceutical (OTCPK:CSMYF) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical PEG Ratio Competitor Comparison
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical PEG Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's PEG Ratio distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
COSMOS Pharmaceutical (CSMYF) has a PEG Ratio of 2.33 as of Jul. 13, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on COSMOS Pharmaceutical and its competitors. This is 16% below median its historical median of 2.77. Over the past decade, COSMOS Pharmaceutical's PEG Ratio has ranged from 1.51 to 9.97. According to the industry distribution chart, COSMOS Pharmaceutical ranks #163 out of 224 companies in the Healthcare Providers & Services industry, placing it in the top 72.8%.
Is COSMOS Pharmaceutical's PEG Ratio too high?
COSMOS Pharmaceutical's current PEG Ratio of 2.33 is 16% below median its 10-year median of 2.77. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 9.97. The Healthcare Providers & Services industry median PEG Ratio is 1.39. COSMOS Pharmaceutical's value of 2.33 is 67.6% above this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #163 out of 224 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's PEG Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #163 out of 224 companies for PEG Ratio. This places COSMOS Pharmaceutical in the lower half of its industry. The industry median PEG Ratio is 1.39. COSMOS Pharmaceutical's value of 2.33 is 67.6% above this benchmark. Historically, COSMOS Pharmaceutical's own PEG Ratio has ranged from 1.51 to 9.97 over the past decade. While the company's 10-year median is 2.77 vs. the industry median of 1.39, COSMOS Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Healthcare Providers & Services company?
The median PEG Ratio among Healthcare Providers & Services companies is 1.39, based on 224 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current PEG Ratio of 2.33 is 67.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median PEG Ratio is 1.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current PEG Ratio is 2.33, which is 16% below median its own 10-year median of 2.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $50.48, compared to a current price of $37.06 — trading 26.6% below its estimated fair value. The current PEG Ratio is 2.33, which is 16% below median its 10-year median of 2.77 and 67.6% above the Healthcare Providers & Services industry median of 1.39. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current PEG Ratio is 2.33 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 26.6% below its estimated GF Value™ of $50.48.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
PEG Ratio: 2.33 (16% below median its 10-year median of 2.77)
GF Value™: $50.48 vs. price of $37.06 (26.6% below fair value)
Industry Position: 67.6% above the Healthcare Providers & Services median (#163 of 224)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
